Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 4:31 AM
Ignite Modification Date:
2025-12-25 @ 4:31 AM
NCT ID:
NCT05515718
Eligibility Criteria:
Inclusion Criteria:
* Patient whose age is ≥ 18 years
* Patient with a suspicion of proximal femoral fracture at the emergency triage, defined as direct traumatism on hip or fall associated with hip pain and/or clinostatism and/or lower extremity deformity with, typically, shortening of the externally rotated limb
* Patient with a verbal numerical pain rating ≥ 7 on emergency triage
* Patient with a diagnosis of ESF fracture made on x-rays in the emergency department
* Patient with a normal lower extremity neurovascular examination
* Anticipated preoperative delay of at least 3 hours
* Patient affiliated to a health insurance plan
* French-speaking patient
* Patient or relative who has given free, informed and written consent
Exclusion Criteria:
* Patient with multiples trauma
* No surgical treatment decided by the orthopedic team
* Prior femoral nerve block performed during pre-hospital time
* Patient was not walking before the fracture
* Patient has received opioids prior to ED admission (by home caregivers or as part of usual treatment) or buprenorphine or nalbuphine
* Contraindications to opioids: acute respiratory failure, acute liver failure, epilepsy not controlled by treatment, allergy; documented severe intolerance to morphine
* Contraindications to loco-regional anesthesia: constitutional or acquired coagulation disorder (anticoagulant treatment, acute hepatic failure), skin infection or wound near to the potential injection site, acute failure of an underlying disease, allergy to Ropivacaine or chlorhexidine
* Patient already included in a type 1 interventional research protocol (RIPH1)
* Patient under guardianship or curatorship
* Patient deprived of liberty
* Patient under court protection
* Pregnant or breastfeeding patient
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT05515718
Study Brief:
Protocol Section:
NCT05515718